AMCAD BIOMED

AmCad BioMed Corporation (AmCad) was founded in 2008 and was listed on Taipei Exchange in the March of 2015 (Ticker: 4188). Our breadth of expertise, from R&D to commercialization, have resulted in world’s first FDA cleared ultrasound Computer-Assisted Detection (CAD) devices. AmCad is committed to assisting medical professionals in making efficient and accurate diagnosis through the support of detailed sonographic visualization and quantification. By integrating AI technology with clinicians' expertise, AmCad will continue to pioneer best-in-class imaging solutions that anticipate mainstream medical needs.